Scholarlink

Background <p>Sarcopenia, the progressive loss of skeletal muscle mass and function, needs upstream, low-burden tools for early detection and high-frequency monitoring, especially in older adults. Conventional assessments such as handgrip strength and gait speed mainly capture downstream impairment and may miss early physiological change. The tongue-coating microbiome is an emerging, measurable niche on the oral–gut–muscle axis that may provide proximal signals of metabolic, inflammatory, and circadian status.</p> Methods <p>We performed a narrative summary of recent evidence on tongue–gut coupling, mapped plausible mechanisms to muscle regulation, and evaluated the feasibility of tongue-based measurement. We propose a minimal methods set (fixed pre-breakfast sampling, strict low-biomass quality control, AI-assisted standardized tongue imaging, saliva assays integrated with multi-omics) and a three-tier metric structure aligned to the minimal clinically important difference (MCID) for functional endpoints.</p> Results <p>Evidence supports links across three axes: metabolic (microbial metabolites such as short-chain fatty acids and niacin that modulate mitochondrial energetics and anabolism), inflammatory (oral dysbiosis and barrier disruption amplifying systemic inflammation via lipopolysaccharide, Toll-like receptor 4, and NF-κB signaling), and circadian (microbiome rhythms coupled to eating and sleep timing). The tongue coating forms a stable niche suitable for frequent follow-up. An upstream–midstream–downstream metric stack enables MCID-anchored interpretation. Current data are limited and heterogeneous, so tongue-derived metrics should complement stool testing and functional standards.</p> Conclusions <p>Tongue-based monitoring is a practical adjunct for earlier risk signaling and community-level follow-up. Priorities are multicenter validation, interpretable and device agnostic models, and axis-stratified trials to define when and for whom tongue-derived signals add MCID-level clinical value. Because direct longitudinal human evidence linking tongue-coating signals to clinically meaningful sarcopenia outcomes remains limited, we frame the tongue-coating microbiome primarily as a hypothesis-driven, upstream monitoring niche and outline testable priorities for validation and translation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From mouth to muscle: mechanistic and interventional perspectives on the tongue-coating microbiome in sarcopenia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Xin Zhao,
  • Yurong Weng,
  • Rong Huang,
  • Yaomin Hu

摘要

Background

Sarcopenia, the progressive loss of skeletal muscle mass and function, needs upstream, low-burden tools for early detection and high-frequency monitoring, especially in older adults. Conventional assessments such as handgrip strength and gait speed mainly capture downstream impairment and may miss early physiological change. The tongue-coating microbiome is an emerging, measurable niche on the oral–gut–muscle axis that may provide proximal signals of metabolic, inflammatory, and circadian status.

Methods

We performed a narrative summary of recent evidence on tongue–gut coupling, mapped plausible mechanisms to muscle regulation, and evaluated the feasibility of tongue-based measurement. We propose a minimal methods set (fixed pre-breakfast sampling, strict low-biomass quality control, AI-assisted standardized tongue imaging, saliva assays integrated with multi-omics) and a three-tier metric structure aligned to the minimal clinically important difference (MCID) for functional endpoints.

Results

Evidence supports links across three axes: metabolic (microbial metabolites such as short-chain fatty acids and niacin that modulate mitochondrial energetics and anabolism), inflammatory (oral dysbiosis and barrier disruption amplifying systemic inflammation via lipopolysaccharide, Toll-like receptor 4, and NF-κB signaling), and circadian (microbiome rhythms coupled to eating and sleep timing). The tongue coating forms a stable niche suitable for frequent follow-up. An upstream–midstream–downstream metric stack enables MCID-anchored interpretation. Current data are limited and heterogeneous, so tongue-derived metrics should complement stool testing and functional standards.

Conclusions

Tongue-based monitoring is a practical adjunct for earlier risk signaling and community-level follow-up. Priorities are multicenter validation, interpretable and device agnostic models, and axis-stratified trials to define when and for whom tongue-derived signals add MCID-level clinical value. Because direct longitudinal human evidence linking tongue-coating signals to clinically meaningful sarcopenia outcomes remains limited, we frame the tongue-coating microbiome primarily as a hypothesis-driven, upstream monitoring niche and outline testable priorities for validation and translation.